As of May 27
| +0.28 / +4.37%|
The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 25.00, with a high estimate of 25.00 and a low estimate of 25.00. The median estimate represents a +274.25% increase from the last price of 6.68.
The current consensus among 1 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.